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Abstract: Japanese encephalitis virus (JEV), a mosquito-borne zoonotic flavivirus, is an enveloped
positive-strand RNA virus that can cause a spectrum of clinical manifestations, ranging from mild
febrile illness to severe neuroinvasive disease. Today, several killed and live vaccines are available
in different parts of the globe for use in humans to prevent JEV-induced diseases, yet no antivirals
are available to treat JEV-associated diseases. Despite the progress made in vaccine research and
development, JEV is still a major public health problem in southern, eastern, and southeastern Asia,
as well as northern Oceania, with the potential to become an emerging global pathogen. In viral
replication, the entry of JEV into the cell is the first step in a cascade of complex interactions between
the virus and target cells that is required for the initiation, dissemination, and maintenance of infection.
Because this step determines cell/tissue tropism and pathogenesis, it is a promising target for antiviral
therapy. JEV entry is mediated by the viral glycoprotein E, which binds virions to the cell surface
(attachment), delivers them to endosomes (endocytosis), and catalyzes the fusion between the viral
and endosomal membranes (membrane fusion), followed by the release of the viral genome into the
cytoplasm (uncoating). In this multistep process, a collection of host factors are involved. In this
review, we summarize the current knowledge on the viral and cellular components involved in JEV
entry into host cells, with an emphasis on the initial virus-host cell interactions on the cell surface.
Keywords: Japanese encephalitis virus; flavivirus; viral replication; viral entry; attachment; binding;
endocytosis; internalization; membrane fusion; virus-host interaction
1. Introduction: JEV Is a Mosquito-Borne Neurotropic Flavivirus
Japanese encephalitis virus (JEV) is a member of the genus Flavivirus, family Flaviviridae [1,2].
Most flaviviruses replicate in both hematophagous arthropod vectors (i.e., mosquitoes and ticks)
and vertebrate animal hosts (e.g., mammals and birds) [3–7], but some infect only arthropods
(e.g., mosquitoes and sand flies) or almost exclusively vertebrates (e.g., bats and rodents) [8–12].
Based on the host range and choice of vector species, flaviviruses can be divided into four
groups [10–12]: mosquito-borne, tick-borne, arthropod-restricted, and vertebrate-restricted viruses,
of which the last group is commonly referred to as no known vector viruses. Many of the mosquito-
and tick-borne flaviviruses are the major emerging and re-emerging pathogens that present a global
challenge to human and animal medicine [13–16]. Of the mosquito-borne flaviviruses, JEV is the
prototype member of the Japanese encephalitis (JE) serogroup [17] that also includes the West Nile virus
(WNV), Murray Valley encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), and four other
lesser known flaviviruses, namely the Usutu virus, Koutango virus, Yaounde virus, and Cacipacore
virus [18,19]. Although antigenically distinct, JEV is genetically close to several medically important
mosquito-borne flaviviruses, such as the Zika virus (ZIKV), dengue virus (DENV), and yellow fever
virus (YFV) [19–21], as well as the tick-borne encephalitis virus (TBEV) [22].
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JEV is the etiological agent of JE, a serious neurological disease characterized by extensive
inflammation in the central nervous system [23,24]. JE is the most common form of viral encephalitis
occurring in the Asia-Pacific region, particularly in southern, eastern, and southeastern Asia, as well as
northern Oceania [25–29]. Initially seen in Japan, outbreaks of “summer encephalitis”, presumably
caused by JEV infection, were described as early as 1871, but it was not until 1924 that the first cases of
JE were diagnosed [30]. Since then, JEV has become prevalent in much of Asia, with a fatality rate of up
to ~30% [31] despite multiple JE vaccines having been made commercially available in this region [32]:
Its geographic boundaries have continued to expand southward into Papua New Guinea [33,34] and
Australia [35–40], eastward through the Pacific Islands [41], and westward into Pakistan [42] and China
(Tibet) [43,44]. Surprisingly, in Italy, JEV RNA was detected by RT-PCR assays in dead birds during
1997–2000 and field-collected mosquitoes in 2010 [45,46], raising concern regarding the long-distance
spread of the virus from the Asia-Pacific region and its potential autochthonous transmission in
Europe [47]. Likewise, the emergence of JEV in the Western Hemisphere is also conceivable [48].
2. JEV Is a Zoonotic Pathogen Capable of Infecting a Wide Range of Animal Species
JEV is transmitted among multiple vertebrate hosts primarily through the bite of an infected
mosquito. In most Asian countries, Culex tritaeniorhynchus is known as the primary mosquito vector
for JEV transmission [49–54]; in Australia, on the other hand, Cx. annulirostris is identified as the
main vector involved in the introduction and spread of JEV [36–38,55]. Also, JEV has been isolated
or detected, albeit at various frequencies, in other wild-caught Culex mosquitoes (e.g., Cx. annulus,
Cx. bitaeniorhynchus, Cx. fuscocephala, Cx. gelidus, Cx. orientalis, Cx. pipiens, Cx. pseudovishnui, Cx.
quinquefasciatus, and Cx. vishnui), suggesting that they may play a role in local JEV transmission [45,50,
52,53,55–64]. Similarly, recent experimental studies on the vector competence of European mosquitoes
have shown that Cx. pipiens and three Aedes species (Ae. albopictus, Ae. detritus, and Ae. japonicus) are
susceptible to JEV infection in a laboratory setting [65–67]. Moreover, JEV infection has been detected
in field-collected or experimentally inoculated non-Culex mosquitoes, such as Ae. albopictus, Ae. vexans,
Armigeres subalbatus, and Mansonia uniformis, and three Anopheles species (An. minimus, An. sinensis,
and An. tessellatus), raising the question of whether they can act as potential vectors under certain
environmental conditions [50,68,69]. Furthermore, JEV can be passed directly from an infected female
Culex or non-Culex mosquito to her eggs, suggesting the transovarial transmission as a mechanism
by which the virus overwinters in the environment [70–73]. In addition, in terms of non-vector-borne
transmission, a recent report has indicated that JEV can be transmitted through the transfusion of
contaminated blood products [74].
The natural cycle of JEV involves numerous vertebrate hosts. In Asia, domestic pigs and water
birds have been recognized as the two most important JEV-amplifying hosts, since they are generally
asymptomatic following infection, but develop high-titer viremias sufficient to transmit the virus to
engorging mosquitoes [75–82]. In sows, it is noteworthy that JEV infection during pregnancy often
causes abortions and stillbirths [83–86]. Bats, along with migratory birds, may play a role in the
overwintering and dispersal of JEV, as suggested by detection of the virus and its IgG antibody [87–92].
On the other hand, horses, like humans, are considered to be incidental hosts that sometimes develop
fatal encephalitis following JEV infection, but are not believed to be a significant source of the virus
for mosquitoes, although they may occasionally develop viremia that allows mosquito infection,
because of their small population size and long generation time [93–101]. In cows, JEV rarely causes
neurological disorders [102–106], and little or no viremia is typically detected [107]. Serological
surveys and experimental infection studies have suggested that JEV can subclinically infect other
vertebrate animals, such as dogs, goats, sheep, buffaloes, boars, raccoons, raccoon dogs, ducks,
and chickens [108–114], underlining the need to investigate their potential roles in JEV ecology [115].
Notably, ducklings and chicks under two weeks of age have been shown to develop considerably
high viremias following JEV infection, but the development of viremia is inversely correlated with
the age of the animals at infection [116]. Interestingly, JEV-infected pigs are demonstrated to shed the
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virus in oronasal secretions [117] and transmit it to co-housed naive pigs in the absence of mosquitoes,
suggesting a mode of viral transmission during mosquito-free seasons [118]. Further studies are
needed to understand the dynamic interactions between the virus, mosquito vectors, and vertebrate
hosts under certain geo-environmental and eco-agricultural conditions [119–121].
3. JEV Is a Small Enveloped Positive-Strand RNA Virus
3.1. Genome Structure and Gene Expression
JEV is an enveloped RNA virus with a linear, single-stranded, and positive-sense RNA genome of
~11 kb in length (Figure 1A). The genomic RNA has a methylated cap structure at its 5′ end, but lacks
a poly (A) tail at the 3′ end [122–126]. It has one long open reading frame (ORF) encoded between
the two short, but highly structured, 5′ and 3′ non-coding regions (NCRs) that form a long-range
intramolecular RNA-RNA interaction to regulate viral translation and RNA replication [127–131].
In addition to the viral genomic RNA, a group of short non-coding subgenomic RNAs (~0.2–0.5 kb)
is also accumulated to high levels in a diverse range of mammalian and insect cells infected with
JEV and other flaviviruses as a result of incomplete degradation of the genomic RNA caused by the
stalling of the cellular 5′→3′ exoribonuclease Xrn1 just upstream of a higher-order structure in the
3′NCR [132–136]. The generation of this subgenomic RNA may cause the suppression of Xrn1 and the
dysregulation of cellular mRNA stability [137], thereby disrupting the host’s innate immune responses
and contributing to viral replication and pathogenesis [138–140].
The ORF in the JEV genomic RNA encodes a polyprotein precursor of ~3432 amino acids, which is
cleaved into at least 10 distinct products [141,142], i.e., three structural (capsid, C; premembrane,
prM; and envelope, E) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5)
proteins (Figure 1B,C). In flaviviruses, the site-specific proteolysis of the polyprotein is catalyzed co-
and post-translationally by a set of four different proteases: (i) the host signal peptidase responsible for
cleaving at the C-prM, prM-E, E-NS1, and NS4A-NS4B junctions within the lumen of the endoplasmic
reticulum (ER) [143–148]; (ii) the two-component viral protease NS3 + NS2B [149] required for cleaving
at the NS2A-NS2B, NS2B-NS3, NS3-NS4A, and NS4B-NS5 junctions, as well as at internal sites within
the C and NS4A proteins on the cytoplasmic face of the ER membrane [143,144,150–155]; (iii) the host
furin or furin-like protease mediating the final cleavage of prM to M in the trans-Golgi network [156];
and (iv) an unknown host protease capable of cleaving at the NS1-NS2A junction [157–159]. In addition
to the aforementioned 10 proteins, an NS1 isoform (NS1′) is also produced during infection with JEV
and other JE serogroup members as a result of −1 translational frameshifting occurring at codons
8–9 of NS2A [160–163].
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Figure 1. Genome organization and gene expression of Japanese encephalitis virus (JEV). (A) Genome 
organization. The genetically well-characterized JEV strain, CNU/LP2, contains a single-stranded 
positive-sense RNA genome of 10,968 nucleotides in length, consisting of a methylated cap at the 5′ 
end, followed by a 95-nucleotide 5′ non-coding region (5′NCR), a 10,299-nucleotide open reading 
frame (ORF), and a 574-nucleotide 3′NCR [164,165]. (B) Gene expression. The single ORF encoded in 
the viral genome produces two precursor polyproteins, a full-length 3432-amino acid polyprotein 
(ppC-NS5) and its C-terminally truncated 1198-amino acid polyprotein (ppC-NS1′), the latter of which 
is expressed by a −1 ribosomal frameshift (FS) event that occurs between the codons 8 and 9 of NS2A, 
adding 52 extra amino acids to the C-terminus of NS1 (designated NS1′). Each of the two polyproteins 
is cleaved by host- and virus-encoded proteases to yield three structural (green) and at least seven 
nonstructural (orange) proteins. The flavivirus-conserved cleavage sites and the length of cleavage 
products are indicated. NS3 consists of an N-terminal serine protease (PRO) domain and a C-terminal 
RNA helicase (HEL) domain, and NS5 consists of an N-terminal methyltransferase (MET) domain 
and a C-terminal RNA-dependent RNA polymerase (RDRP) domain. Asterisks indicate four N-linked 
glycosylation sites (NXT/S) found in the pr portion of prM (Asn15), E (Asn154), and NS1/NS1′ (Asn130 
and Asn207). (C) Polyprotein membrane topology. The membrane orientation of the 10 major JEV 
proteins is predicted on the endoplasmic reticulum (ER) membrane, based on previous work with 
other flaviviruses [142,166–169]. 
3.2. Viral Replication Cycle 
JEV is a flavivirus containing an inner nucleocapsid [170], a disordered structure made of the 
genomic RNA and helix-rich C proteins [171–173]. The nucleocapsid is enclosed by a lipid bilayer, 
which is in turn encased in a well-organized outer protein shell composed of the membrane-anchored 
prM/M and E proteins [174–179]. Basically, JEV shares a common strategy for viral replication with 
other flaviviruses (Figure 2). Viral entry is a dynamic process, defined by a series of interactions 
between the virus and the host cell that starts with nonspecific binding of the viral glycoprotein E to 
one or more cellular attachment factors on the cell surface [180–185]. This attachment step serves to 
concentrate the virions at the cell surface to facilitate the specific interaction of the viral E glycoprotein 
with a cellular entry factor(s) [186–188], directing the classical clathrin-dependent endocytosis [189–
200] or non-classical clathrin-independent endocytosis pathways [201–206], presumably in a cell 
type-restricted fashion. Once inside the endosome, the viral E glycoprotein undergoes low pH-
induced conformational changes [207–213], triggering the fusion of viral and host endosomal 
membranes [214–221]. Following membrane fusion, the genomic RNA is released into the cytoplasm, 
where it is translated into two precursor polyproteins (with or without a ribosomal frameshifting at 
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where it is translated into two precursor polyproteins (with or without a ribosomal frameshifting at
the beginning of NS2A-coding region) that are cleaved to yield three structural (C, prM, and E) and at
least seven nonstructural (NS1 to NS5) proteins, along with NS1′ [141,142].
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Figure 2. Replication cycle of JEV. A viral particle binds initially to a target cell through one or more 
attachment factors on the cell surface (Attachment). Subsequently, the virion interacts with an entry 
factor(s), which triggers receptor-mediated clathrin-dependent or clathrin-independent endocytosis 
of the bound virion (Endocytosis). Following internalization, the virion travels through the 
endosomal maturation pathway until endosomal acidification triggers the low pH-induced activation 
of the viral E glycoprotein, enabling the fusion between viral and endosomal membranes (Membrane 
fusion). Upon release of the viral genomic RNA into the cytoplasm (Uncoating), it is translated into 
two overlapping polyproteins as the result of a −1 ribosomal frameshift event in association with the 
ER (Translation). The polyproteins are co- and post-translationally cleaved to generate the mature 
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(RNA replication). Viral assembly proceeds with the concomitant interaction of viral RNA with the 
three structural proteins (C, prM, and E), promoting the budding of immature particles into the lumen 
of the ER (Assembly). The immature virions, containing heterodimers of prM and E, are then 
transported through the trans-Golgi network, where prM is cleaved to form mature virions containing 
homodimers of M and E (Maturation). Finally, both partially and completely mature virions are 
released into the extracellular milieu (Release). 
After translation, all seven nonstructural proteins, together with the poorly understood host 
factors [222], are involved directly or indirectly in the genomic RNA replication that occurs in the 
virus-induced ER-derived membraneous organelle [223–227] housing the replication complexes 
[123,228]. Viral RNA replication is catalyzed by NS3 and NS5 [229], the two largest and most 
conserved nonstructural proteins that coordinate their multiple enzymatic activities in negative-
strand RNA synthesis, positive-strand RNA synthesis, RNA capping, and cap methylation 
[123,149,230]. During or shortly after RNA replication, a complex of the newly synthesized genomic 
RNA and C proteins is enveloped by two viral glycoproteins (prM and E [231]) on the ER membrane 
to produce the immature virion (~60 nm diameter) covered with 60 protruding spikes, each composed 
of three parallel prM:E heterodimers [232–235]. The immature virions are believed to pass through 
the constitutive secretory pathway to the extracellular space. During this exocytosis, viral maturation 
occurs in the trans-Golgi network through the furin-mediated cleavage of the prM protein to M 
Figure 2. Replication cycle of JEV. A viral particle binds initially to a target cell through one or more
attachment factors on the cell surface (Attachment). Subsequently, the virion interacts with an entry
factor(s), which triggers receptor-mediated clathrin-dependent or clathrin-independent endocytosis of
the bound virion (Endocytosis). Following internalization, the virion travels through the endosomal
maturation pathway until endosomal acidification triggers the low pH-induced activation of the viral
E glycoprotein, enabling the fusion between viral and endosomal membranes (Membrane fusion).
Upon release of the viral genomic RNA into the cytoplasm (Uncoating), it is translated into two
overlapping poly roteins as the result of a −1 ribosomal frameshift event in association it t e
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the ER (Assembly). The immature virions, containing heterodimers f prM and E, are then transport d
hrough he trans-Golgi network, where prM is cleaved to form mature vi ions containing homodimers
of M and E (Maturation). Finally, both partial y and completel mature virions are released into th
extr c llular mili u (Release).
After translation, all seven nonstructural proteins, together with the poorly understood host
factors [222], are involved directly or indirectly in the genomic RNA replication that occurs in the
virus-induced ER-derived membraneous organelle [223–227] housing the replication complexes [123,228].
Viral RNA replication is catalyzed by NS3 and NS5 [229], the two largest and most conserved
nonstructural proteins that coordinate their multiple enzymatic activities in negative-strand RNA
synthesis, positive-strand RNA synthesis, RNA capping, and cap methylation [123,149,230]. During or
shortly after RNA replication, a complex of the newly synthesized genomic RNA and C proteins is
enveloped by two viral glycoproteins (prM and E [231]) on the ER membrane to produce the immature
virion (~60 nm diameter) covered with 60 protruding spikes, each composed of three parallel prM:E
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heterodimers [232–235]. The immature virions are believed to pass through the constitutive secretory
pathway to the extracellular space. During this exocytosis, viral maturation occurs in the trans-Golgi
network through the furin-mediated cleavage of the prM protein to M [156,236–238], accompanied
by a significant structural rearrangement of the M and E proteins, to generate the mature virion
(~50 nm diameter), which is covered by 30 flat densely packed rafts, each composed of three parallel
E:M:M:E heterotetramers [232,239,240]. In addition to the M-containing completely mature virions,
prM-containing partially mature, but still infectious, virions are also shown to be produced [241–244],
although viral infectivity is likely compromised [245]. Overall, viral replication takes place entirely in
the cytoplasm; however, two viral proteins, C [246–250] and NS5 [251–257], are not only detected in
the cytoplasm, but are also found in the nucleus [258]. The precise role of their nuclear localization in
viral replication and pathogenesis requires further investigation.
4. Viral Entry Is the First Step in the Infection Process
Viral entry is the first step in an orchestrated process of virus-host interactions that is not only
required for the initiation, dissemination, and maintenance of productive infection [259,260], but also
represents a critical determinant of cell/tissue tropism and pathogenesis [261]. JEV entry is thus a
promising target for antiviral therapy and offers multiple points for intervention [262]: attachment,
endocytosis, membrane fusion, and uncoating (see a recent review article for a detailed description
of small-molecule inhibitors targeting flavivirus entry [263]). Identifying the viral and host factors
involved in JEV entry is a prerequisite to elucidating the molecular mechanisms of viral entry and
developing novel therapeutic and preventive antivirals. In recent years, tremendous progress has been
made in understanding the viral components required for the various steps of JEV entry, but little is
known about the cellular components involved in this important process.
4.1. Virus Structure
Using cryo-electron microscopy (EM) and image reconstruction techniques, Wang and coworkers
have determined the 4.3-Å three-dimensional structure of JEV [176]. On the surface of the mature JEV,
180 copies of each of the M and E proteins are organized into 30 flat, densely packed rafts. Each of
these rafts is composed of three parallel E:M:M:E heterotetramers, with the E proteins forming the
smooth outer protein shell and the M proteins being buried underneath it (Figure 3A), as seen in the
cryo-EM structures initially of DENV [174,179] and WNV [175], and lately ZIKV [177,178]. The JEV
E monomer, like that of other flavivirus E proteins, consists of three topologically distinct segments
(Figure 3B,C): (i) a banana-shaped ectodomain, which mediates receptor binding and membrane
fusion; (ii) a “stem” region, which includes three perimembrane helices lying nearly horizontal
on the viral membrane underneath the ectodomain; and (iii) an “anchor” region, which contains
two antiparallel membrane-embedded helices [240,264–266]. Notably, the E ectodomain adopts a
three-domain architecture, with domain I (E-DI) lying at the interface between domains II (E-DII) and
III (E-DIII) (Figure 3C): (a) E-DI has the glycan loop carrying an N-linked carbohydrate chain attached
to Asn154 and a string of six closely dispersed basic residues (Lys279 to Lys297) mapped in the last strand
I0 of E-DI and the linker between E-DI and DIII; (b) E-DII contains the fusion loop at its tip and several
potentially functionally important loops (e.g., h-i, i-j, and k-l loops) on its side; and (c) E-DIII has the
Arg-Gly-Asp (RGD) motif and is implicated in receptor binding and antibody neutralization [267–284].
In contrast, the JEV M monomer contains a flexible N-terminal loop, followed by an amphipathic
helix lying on the membrane and two antiparallel helices embedded in the membrane (Figure 3C).
The N-terminal loop of M participates in electrostatic and hydrophobic interactions with E-DI and
E-DII, and the amphipathic helix of M is involved in hydrogen-bond interactions with E-DII (centered
at Gln264 near helix αB) and the N-terminus of a neighboring M. The E-DI, E-DIII, and the helical stem
region of E are held together by charge interactions.
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the same color are quivalent by icosahedral symmetry. (B) Side view of the E:M heterodimer fitted
into the electron densi y map. Indicated are the ectodomain, stem, and anchor regions of the E protein,
along with the M protein buried underneath it. (C) Ribbon diagram of he E:M:M:E heterotetramer.
Color-coded are he structurally distinct domains/regions of E and M pr teins: E-DI (domain I), E-DII,
E-DIII, E-H1 (helix 1), E-H2, E-H3, E-TM1 (transmembrane 1), E-TM2, M-H, M-TM1, and M-TM2.
Also highlighted are the functionally important structur l components i the E ect domain: glycan
loop and a stretch of basic residues in E-DI; fusion loop, h-i loop, i-j loop, k-l loop, and αB helx
in E-DII; and Arg-Gly-Asp (RGD) motif in E-DIII. In all cases, one molecule is used for labeling.
The high-resolution images of t is figure were ki dly provided by Dr. Xiangxi Wang [176].
4.2. Attachment
4.2.1. Viral Components
Despite recent advances in our understanding of the near-atomic resolution cryo-EM structure of
JEV [176], the mechanisms by which the virion bi ds to its cellul r receptors are not fully understood.
In J [285–287] and other mosquito-born flaviviruses [181–185,243,288–294], the presence of
a N-linked glycan in E-DI (Figure 4A) and an RGD motif in E-DIII (Figure 4B) on the viral
membrane suggests a mechanism of relatively nonspecific i teractions with the carbohydrate-binding
lectins and RGD-binding integrins on the cell surface, respectively; in agreement with this notion,
locking/alteration of either the N-glycosylation or RGD motif generally negatively affects viral entry
to varying degrees, but fails to abolish the process [182,243,285–295]. Also, strin of six closely
dispersed basic residues (Lys279 to Lys297) located in the last strand I0 of E-DI and the linker between
E-DI an E-DIII (Figure 4C), conserved among the members of the JE and DEN serogroups, as been
proposed as a potential binding site for glycosaminoglycans (GAGs) [180,295]. However, the cry -EM
structure of JEV in icates that, of the six basic r sidues, four central residues are buried, suggesting that
conformational changes are required to m ke this potential GAG-binding sit accessible to GAGs [176].
Most intri uingly, the cryo-EM structure of JEV, combined with structure-based amino acid sequenc
lignment f the E proteins from seven different flaviviruses (JEV, WN , MVEV, SLEV, ZIKV, DENV,
and YFV), reveals an u usual “hole” n the viral surface, with distinct electrostatic characteristics
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(Figure 4D) that could be a potential receptor-binding site for JEV and other members of the JE
serogroup [176,296]. Thus, the viral components and their interacting cellular counterparts required
for triggering flavivirus internalization after binding on the cell surface are still elusive.
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prov ded by Dr. Xiangxi Wang [176].
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4.2.2. Cellular Components
JEV maintains a natural transmission cycle among birds, pigs, and other vertebrate hosts,
with mosquito vectors; in vitro, JEV can infect and replicate in a broad range of cell types originating
from many different vertebrate and invertebrate species [165], suggesting that there is probably more
than one host factor responsible for viral entry. The host factors documented to be involved in the
early steps of JEV entry to date are summarized in Table 1.
Table 1. Cellular components involved in the early steps of JEV entry.
Cellular Component Type/Property Host Cell Virus
Heparan sulfate Glycosaminoglycan Mammal JEV, WNV, MVEV, ZIKV, DENV, YFV, TBEV
DC-SIGN/L-SIGN C-type lectin Mammal JEV, WNV, DENV
MR C-type lectin Mammal JEV, DENV, TBEV
CLEC5A C-type lectin Mammal JEV, DENV
LSECtin C-type lectin Mammal JEV
mosGCTL-7, 1, and 3 C-type lectin Mosquito JEV, WNV, DENV
αvβ3 Integrin Mammal JEV, WNV
HSP70/HSC70/GRP78 70-kDa heat shock protein Mammal, Mosquito JEV, DENV
HSP90 90-kDa heat shock protein Mammal JEV, DENV
37/67-kDa LR High-affinity laminin receptor Mammal JEV
CD4 Immunoglobulin superfamily Mammal JEV
CD14 Pattern recognition receptor Mammal JEV
Vimentin Type III intermediate filament Mammal JEV
LDLR Low-density lipoprotein receptor Mammal JEV
74-kDa protein Not characterized Mammal JEV
53-kDa protein Not characterized Mosquito JEV
Glycosaminoglycans (GAGs)
In JEV [297–300] as well as six other pathogenic flaviviruses [180,274,300–312], GAGs, a family of
linear, polydisperse, sulfated polysaccharides [313] (such as the heparan sulfates found in all animal
tissues), serve as one of the initial attachment factors for concentrating viral particles on the cell surface
prior to the interaction with other molecules. Negatively charged sulfate groups on the GAGs can
bind to a cluster of positively charged residues on the viral E glycoprotein [314]. In the case of JEV,
a role for GAGs in viral attachment has been demonstrated by (i) competition for viral binding to
hamster kidney-derived BHK-21 cells by highly sulfated GAGs, such as heparin and dextran sulfate;
(ii) pretreatment of BHK-21 cells with sodium chlorate, a potent sulfation inhibitor; (iii) a comparison of
the binding efficiency of the virus to the hamster ovary-derived wild-type CHO cell line and its mutants
with defects in GAG biosynthesis; and (iv) the identification of single net-positive-charge amino acid
changes (e.g., E49K, E138K, E306K, D389G/D389N, and E390G) in the E-DI or E-DIII region, with an
enhanced binding capacity for GAGs [297–300,315]. Interestingly, most if not all cell culture-adapted
JEVs, including a live-attenuated JE vaccine SA14-14-2 strain derived from its virulent parental SA14
strain, exhibit an increased ability to bind heparin, a highly sulfated GAG [274,300,315]. Similar
results have also been observed for the live-attenuated YF vaccine 17D strain derived from its virulent
parental Asibi strain [301]. Thus, an increased binding affinity for highly sulfated GAGs seems to be
favorable for flavivirus growth in cell culture, and GAG-adapted flaviviruses tend to show attenuated
phenotypes in vivo.
C-Type Lectins
One set of attachment factors involved in flavivirus entry is the family of C-type lectins, which are
Ca2+-dependent glycan-binding proteins that recognize carbohydrate moieties on the surface of invading
pathogens, act as the receptors for internalization, and deliver the pathogens to endosomes for antigen
presentation, thereby activating host defense systems [316,317]. Of particular interest are (i) the
dendritic cell-specific intercellular adhesion molecule (ICAM)-3-grabbing non-integrin (DC-SIGN,
also called CD209 and CLEC4L [318,319]), which is highly expressed on subsets of dendritic cells (DCs)
and macrophages; and (ii) the liver/lymph node-specific ICAM-3-grabbing non-integrin (L-SIGN,
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also known as CD209L, CLEC4M, and DC-SIGNR for “DC-SIGN-related” [320–322]), which is mainly
expressed on endothelial cells in the liver and lymph nodes [323]. For JEV, siRNA knockdown and
antibody blocking experiments, combined with the characterization of a DC-SIGN mutant defective in
its internalization, have shown that DC-SIGN is important for viral binding to DCs that is mediated by
an N-linked mannose-rich glycan at Asn154 on the viral E protein, but it is dispensable for subsequent
internalization [287]. Similarly, for WNV [181,324] and DENV [182,184,325–329], both DC-SIGN and
L-SIGN have been shown to promote infection via an interaction with an N-glycan(s) at Asn154
(for WNV) and at both Asn67 and Asn153 (for DENV) on the viral E protein.
Based on the work with WNV and DENV, the use of DC-SIGN and L-SIGN as attachment factors
for flaviviruses varies, depending on the number and location of N-glycosylation sites on the viral E
protein [182,183,324,325], as well as on the type of N-glycans linked to these sites, which is determined
by the cells used for virus production [181,324–326]. Although glycosylation profiles may vary in
a given cell line, in general, the high-mannose N-glycans on mosquito cell-produced virions are
recognized well by both DC-SIGN and L-SIGN, whereas the complex N-glycans on mammalian
cell-produced virions are preferentially recognized by L-SIGN. There is a further added level of
complexity because “mosaic” partially mature flaviviruses contain a small, but detectable, amount of
the glycosylated uncleaved prM proteins [330,331], with one to three potential N-glycosylation sites
within the pr region [332] that may directly or indirectly contribute to the lectin-mediated attachment
of flaviviruses to the cell surface [324–326]. Notably, the physiologically relevant functional importance
of DC-SIGN in flavivirus replication and pathogenesis in humans is underlined by the association
of a single nucleotide polymorphism (SNP) found in the promoter region of the DC-SIGN gene
with a greater susceptibility to dengue hemorrhagic fever (SNP rs4804803 [333]) and severe forms of
tick-borne encephalitis (SNP rs2287886 [334]) in certain subpopulations.
There are three other C-type lectins that have been suggested to participate in the early steps of JEV
infection: mannose receptor (MR); C-type lectin domain family 5, member A (CLEC5A); and liver and
lymph node sinusoidal endothelial cell C-type lectin (LSECtin) [286,335–337]. (1) MR is expressed on
subsets of macrophages and DCs, as well as on nonvascular endothelium; it plays multiple important
roles in clearing endogenous molecules, promoting antigen presentation, and modulating cellular
activation and trafficking [338]. A study has shown that the extracellular region of MR binds broadly
to mosquito cell-produced DENV particles and pointedly to mammalian cell-expressed DENV E
ectodomains in a Ca2+-dependent manner; in addition, the cell surface expression of human MR
in mouse embryo-derived 3T3 cells confers DENV binding, and anti-MR antibodies inhibit DENV
infection in human macrophages [335]. The same study has also reported that the extracellular region of
MR binds in enzyme-linked immunosorbent assays to formalin-inactivated JEV and TBEV, although the
nature of this binding has not been characterized [335]. (2) CLEC5A is exclusively expressed on myeloid
cells (e.g., macrophages and monocytes) and associates with a 12-kDa DNAX-activating protein
(DAP12), an adaptor molecule that transduces intracellular signaling involved in innate immunity;
thus, CLEC5A is also known as myeloid DAP12-associating lectin-1 (MDL-1) [339,340]. CLEC5A
has been shown to interact directly with JEV [336] and DENV [337], albeit in a Ca2+-independent
manner, and is capable of inducing DAP12 phosphorylation in macrophages. Unlike DC-SIGN and
L-SIGN, the CLEC5A-JEV/DENV interaction does not promote viral infection, but rather stimulates
the release of proinflammatory cytokines (e.g., TNF-α and MCP-1), thereby potentially contributing to
the pathogenesis of virus-induced inflammatory diseases [336,337]. In the case of both JEV and DENV
infection, the inflammation-associated viral pathogenesis and lethality in mice can be ameliorated by
blocking the CLEC5A-JEV/DENV interaction with anti-CLEC5A antibodies [336,337]. (3) LSECtin
(also known as CLEC4G) is expressed on myeloid cells, as well as on sinusoidal endothelial cells of the
liver and lymph node; it mediates pathogen recognition, uptake, and internalization [317,341]. Using
human B lymphocyte-derived Daudi cells that are non-susceptible to JEV infection, researchers have
recently shown that the ectopic expression of LSECtin renders the cells susceptible to JEV infection.
This infection can be inhibited by N-acetylglucosamine β1–2 mannose (a target for LSECtin) but not by
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mannan (a target for DC-SIGN/L-SIGN) [286]; however, the underlying mechanism of LSECtin in JEV
entry has not been fully defined.
In addition to the mammalian C-type lectins described above, a family of mosquito
galactose-specific C-type lectins (mosGCTLs) has been reported to play a central role in the entry
steps of JEV [342], WNV [343], and DENV [344] in their major Culex/Aedes mosquito vectors.
The original work has shown that mosGCTL-1 (VectorBase accession no. AAEL000563) as a secreted
form of mannose-binding lectin (MBL) binds to WNV in a viral E protein-mediated Ca2+-dependent
manner and brings the mosGCTL-1-WNV complex to its cell surface receptor, mosquito protein
tyrosine phosphatase-1 (mosPTP-1), thereby facilitating WNV entry both in vivo and in vitro [343].
The mosPTP-1 is a mosquito homolog of human CD45 that is expressed on all nucleated cells of
hemopoietic origin [345] and is critical for thymocyte development and activation [346,347] through its
interaction with human MBL [348]. Since CD45 is expressed on hematopoietic cells that are important
for flavivirus pathogenesis and host immunity [349], it will be interesting to determine whether
the human MBL-CD45 interaction can also mediate the entry of flaviviruses into human cells [350].
Moreover, mosquito blood-feeding experiments have demonstrated that WNV infection can be blocked
in vivo with anti-mosGCTL-1 antibodies [343], suggesting a promising new approach to interrupt the
life cycle of WNV in mosquito populations. Similarly, mosGCTL-7 (AAEL002524) and mosGCTL-3
(AAEL000535) have subsequently been shown to be able to mediate the mosquito cell entry of JEV and
DENV, respectively [342,344]. For DENV infection, a genetic association of the exon 1 polymorphisms
of the human MBL gene (MBL2) with dengue hemorrhagic fever has been suggested because variant
alleles and haplotypes related to low production levels of MBL are associated with the severity of
DENV-induced diseases [351]. Further investigation is required to elucidate the underlying mechanism
behind the variation in the usage of specific mosGCTLs for particular flaviviruses, along with distinct
mosPTPs, and the role of the mosGCTL-mosPTP pathway in flavivirus entry.
Integrins
Integrins are a family of cell surface receptors, each composed of two subunits (α and β),
that act as linkers between the extracellular matrix and the actin cytoskeleton, and play a critical
role in the activation and homing of hematopoietic cells [352]. Biochemical and molecular studies
have demonstrated that in monkey kidney-derived Vero or human cervical carcinoma HeLa cells,
the lineage-2 Sarafend strain of WNV binds to αvβ3 integrin, and WNV infection is notably
decreased by pretreatment with anti-αvβ3 antibodies, competition with recombinant αv or β3 protein,
or siRNA knockdown of the β3 subunit; however, somewhat unexpectedly, WNV infection is only
marginally affected by pretreatment with synthetic RGD peptides, an inhibitor of integrin-ligand
interactions [288,353]. It has also been noted that soluble αvβ3 can block WNV infection of Vero cells in
a dose-dependent manner, and the expression of αvβ3 increases the susceptibility to WNV infection of
hamster melanoma CS-1 cells lacking functional integrin [288]. In contrast, another study has shown
that the lineage-1 NY385-99 strain of WNV can infect and replicate in mouse embryonic fibroblasts
lacking functional αvβ3 [354]. Therefore, the discrepancies in these studies suggest that the role of αvβ3
in WNV entry is potentially strain-specific and/or cell type-dependent. Further investigation is needed
to define a potential role of αvβ3 in WNV infection [355]. As previously seen for WNV, pretreatment
with anti-αvβ3 antibodies has been shown to inhibit JEV entry into Vero cells [288]. A potential role
for αvβ3 in JEV entry has also been proposed in hamster kidney-derived BHK-21 cells, based on
shRNA-based gene silencing and antibody/peptide-based blocking experiments using anti-αvβ3
antibodies and synthetic RGD peptides, although their inhibitory effects varied significantly [285].
Other Host Factors
Heat shock proteins (HSPs) were long believed to be cytoplasmic proteins, but their protein- and/or
lipid-mediated association with intracellular and plasma membranes is now well documented [356].
To date, two families of HSPs have been proposed to participate in the early steps of JEV infection,
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possibly in a cell type-dependent manner: (i) three members of the HSP70 family, namely the prototype
HSP70, heat shock cognate protein 70 (HSC70), and glucose-regulated protein 78 (GRP78, also referred
to as BiP for “binding immunoglobulin protein”); and (ii) the prototype HSP90 of the HSP90
family [196,357–362]. The details are as follows: (1) HSC70 derived from Ae. albopictus C6/36 cells
has been shown by co-immunoprecipitation experiments to bind to JEV [357]. In C6/36 cells, gene
knockdown experiments have identified HSC70 isoform D, which is involved in the clathrin-mediated
endocytosis of JEV [196]. (2) HSP70 derived from mouse neuronal Neuro-2a cells has been shown by
virus overlay protein binding assays to interact with JEV; the interaction between HSP70 and the JEV
E protein has been demonstrated by co-immunoprecipitation and immunoblotting [358]. Antibody
blocking experiments using anti-HSP70 antibodies have produced a significant reduction in JEV entry
into Neuro-2a cells [358]. (3) In human hepatoma Huh7 cells, the association of both HSP70 and JEV
E proteins with cholesterol-rich lipid rafts on the cell surface has been shown to be critical for JEV
infection [197,359]. In Huh7 cells, both antibody blocking and siRNA knockdown experiments have
revealed that HSP70, but not HSC70 or GRP78, is crucial for the host cell entry of vesicular stomatitis
virus-based pseudoviruses expressing JEV prM and E proteins [359]. (4) In Neuro-2a cells, however,
a combination of biochemical, genetic, and molecular experiments has shown that GRP78, capable of
interacting with JEV E-DIII, plays multiple roles in the entry and post-entry steps of JEV infection [360].
(5) HSP90 isoform HSP90β, but not HSP90α, is co-localized and co-immunoprecipitated with JEV
E proteins in hamster kidney-derived BHK-21 cells infected with JEV; HSP90β is also shown to be
secreted into the culture supernatant from JEV-infected BHK-21 cells, presumably in association
with released virus particles, promoting viral infectivity or the release of infectious particles [361].
Thus, all the data available to date suggest that several members of the HSP70 and HSP90 families
have pivotal, isoform-specific, and differential roles in JEV entry, depending to some extent on the cell
type, like those documented in DENV entry [363–370].
Several other host factors are thought to promote the infection of various cell types by JEV: (i) the
37/67-kDa high-affinity laminin receptor, CD4, and CD14 in mouse microglial BV-2 cells [362]; (ii) the
type III intermediate filament vimentin in mouse neuroblastoma N18 and human neuroblastoma
HTB-11 cells [371,372], as well as in porcine kidney PS cells [373]; (iii) the low-density lipoprotein
receptor in hamster kidney-derived BHK-21 cells [374]; (iv) a 74-kDa protein in monkey kidney-derived
Vero cells [375]; and (v) a 53-kDa protein in Ae. albopictus C6/36 cells [376]. However, the biological
function and physiological role of these molecules in JEV entry remain to be defined. In addition,
a handful of other cellular components have also been put forward as putative receptors for
one or more of other mosquito-borne flaviviruses, such as WNV, ZIKV, DENV, and YFV: (a) the
phosphatidylserine-recognizing TIM (TIM-1, -3, and -4) and TAM (TYRO3, AXL, and MER) family
members [185,377–388], (b) the phosphatidylserine- and phosphatidylethanolamine-binding protein
CD300a [389], (c) the tight junction component Claudin-1 [390,391], (d) the scavenger receptor
class B type I coupled with apolipoprotein A-I [392], (e) the 37/67-kDa high-affinity laminin
receptor [393,394], (f) CD14-associated molecules [395], (g) the carbohydrate β-N-acetylglucosamine
moiety of glycosphingolipids [396,397], (h) the natural killer cell-activating receptor, NKp44 [398],
and (i) the mosquito cell-derived prohibitin [399] (see two recent review articles for a detailed
description of these molecules [186,400]). Despite these research efforts discussed above, however,
the cell surface receptors and other host factors required for directing JEV, or any other flavivirus, into
the receptor-mediated endocytic pathway and low pH-dependent membrane fusion are still unknown.
4.3. Endocytosis
JEV is internalized from the plasma membrane of host cells to an endosomal compartment
via multiple endocytic routes in vitro [401], largely depending on the types of cell being infected:
(i) the classical clathrin-dependent pathway observed in the mosquito-derived C6/36 [196], hamster
kidney-derived BHK-21 [194], monkey kidney-derived Vero [198,201], porcine kidney-derived
PK15 [195], and mouse neural stem-like C17.2 [197] cells; and (ii) the non-classical clathrin-independent
Pathogens 2018, 7, 68 13 of 38
pathway (e.g., caveolin-dependent pathway) observed in the human neuroblastoma SK-N-SH [202],
mouse neuroblastoma Neuro-2a [201], and rat neuroblastoma B104 [203] cells. In almost all of these
cell lines (BHK-21, Vero, PK15, C17.2, SK-N-SH, Neuro-2a, and B104), the depletion of cholesterol from
the cell membrane with methyl-β-cyclodextrin reduces productive JEV infection [194,195,197,201–203],
suggesting an important role for cholesterol and possibly cholesterol-rich lipid rafts in both
clathrin-dependent and clathrin-independent endocytosis of JEV. Upon internalization, trafficking of
the endocytosed vesicles containing JEV particles to early and recycling endosomes is demonstrated
to be regulated by the two Rab GTPases, Rab5 and Rab11, for clathrin-dependent endocytosis in
BHK-21 cells [194]. In the case of clathrin-independent endocytosis in Neuro-2a cells, JEV-carrying
vesicles are transported to Rab5-positive early endosomes before the release of its genomic RNA into
the cytosol, and this vesicle trafficking is shown to be mediated by the actin-myosin II machinery
that is modulated by the major Rho GTPase RhoA [201]. Similarly, RhoA and Rac1 GTPase-mediated
actin rearrangements are documented to be critical for caveolin-dependent endocytosis of JEV in
SK-N-SH cells [202]. Considering the variations mentioned above, it is necessary to determine the
main endocytic pathway co-opted by JEV for its entry into human neurons in the brain, which are the
major target cells of JEV, and human monocytes and macrophages/DCs in the periphery, which are
likely to be of importance in mediating neuroinvasion.
Among other flaviviruses, WNV is reported thus far to adopt the clathrin-mediated endocytic
pathway for entry into C6/36 [190], Vero [191], and HeLa [402] cells. On the other hand, DENV is
shown to be able to enter the cytosol via an endosomal compartment, not only predominantly by
clathrin-dependent endocytosis (as described in C6/36 [189,192,403], Vero [205,206,404], BSC-1 [193],
NIH3T3 [328], HeLa [193,402], A549 [404], Huh7 [199], HepG2 [200,405], and ECV304 [406] cells and
human monocytes/immature DCs [328,407]) but also partially by clathrin-independent endocytosis
(as described in Vero [204–206,404] and HepG2 [200] cells). It has been noted in Vero cells, however,
that DENV can utilize both clathrin-dependent and clathrin-independent pathways for internalization,
depending on the viral serotype, and the virus can be transported to a different endosomal
compartment prior to membrane fusion, depending on the viral strain, even within the same
serotype [205,404]. Moreover, the main endocytic route employed by DENV in Vero cells is reported
to be altered from a clathrin-independent pathway for C6/36-grown virus to the clathrin-dependent
pathway for Vero-adapted virus [206]. In the case of both DENV and WNV, numerous studies
have indicated the functional importance of cholesterol [204,354,408], cytoskeleton and motor
proteins [189–192,199,328,409,410], and Rab GTPase-regulated vesicle trafficking [193,199,204,205,
328,402] in the process of their entry into various cell lines.
As is true for DENV, YFV is also able to enter HeLa cells via two distinct endocytic routes,
as demonstrated by the finding that the wild-type virulent Asibi strain primarily utilizes the
clathrin-dependent pathway, whereas its attenuated vaccine 17D strain exploits a pathway independent
of both clathrin and caveolin [411]. A mutagenetic analysis has indicated that the strain-specific use
of distinct endocytic pathways for YFV internalization is due to the 12 amino acid differences found
within the viral E protein between Asibi and 17D [411]. Interestingly, the 17D vaccine strain is shown
to enter HeLa and several other human cells more efficiently than does the parental Asibi strain,
resulting in a stronger induction of the cytokine-mediated antiviral response [411]. These data suggest
a potential link between viral entry and the host immune response. It will be interesting to examine
whether the strain-specific use of different endocytic pathways for YFV internalization is maintained
by an isogenic pair of JEV SA14 and SA14-14-2 strains. In summary, JEV and other flaviviruses enter a
wide range of different host cells by viral E protein-directed endocytosis, but the precise endocytic
pathway used for viral internalization is determined by a combination of both the genetic composition
of the viral E protein and the availability of its interacting cellular components in a given cell type.
In cell biology, clathrin-mediated endocytosis is one of the best-studied processes, with a network
of various cellular proteins well characterized to date [412]. These previously known host factors are
generally required for those viruses that usurp the clathrin-mediated endocytic pathway [381,413–418].
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In addition, the interferon-inducible glycosylphosphatidylinositol-anchored lymphocyte antigen 6E
(LY6E) has been found to play a role in facilitating YFV and WNV infection [415,419]. A recent
study has shown that LY6E is required for the clathrin-mediated uptake of several mosquito-borne
flaviviruses (WNV, ZIKV, and DENV) and of transferrin-coated particles that are similar in size
to these virions, but not of free transferrins [420]. Cell biological studies have revealed that the
internalization of these virions and transferrin-coated particles is triggered by the formation of
tubule-like structures of LY6E, which depend on the vacuolar ATPase-associated transmembrane
protein RNASEK (for “ribonuclease kappa”) and microtubules [420–422]. It will be interesting
to test whether this LY6E-mediated size-dependent endocytic pathway is also involved in the
clathrin-mediated uptake of JEV. Furthermore, a genome-wide siRNA screen has identified the human
G protein-coupled receptor kinase 2 (GRK2, also known as ADRBK1) as being involved in promoting
both the entry and RNA replication steps of YFV and DENV [417]. Similar genomic screens using
RNAi and CRISPR/Cas9 approaches have revealed a collection of human host factors that function
at the early stages of DENV and ZIKV infection, of which the ER membrane protein complex (EMC)
is suggested to play a role in a post-attachment step during viral entry [381]. Another large-scale
RNAi screen has discovered a set of insect host factors and their human homologs that are required
for DENV replication, with a subset presumably involved in viral entry [416]. Additional research
is warranted to define the host factors selectively involved in the internalization process of JEV and
other flaviviruses.
4.4. Membrane Fusion and Uncoating
As is true for other flaviviruses, JEV enters its host cells through clathrin-(in)dependent
endocytosis and low pH-triggered membrane fusion, both of which are mediated by the viral
glycoprotein E, a prototypical class II fusion protein [187,330,423–425]. In recent years, a working
model of flavivirus membrane fusion has been established based on the dimeric pre-fusion and
trimeric post-fusion E ectodomain crystal structures and biochemical properties of JEV [296,426],
WNV [427,428], SLEV [429], ZIKV [430], DENV [210,211,240,431–433], and TBEV [208,278], together
with reconstitution of in vitro transient fusion intermediates at different stages of the fusion
process [207,209,212–214,434]. As illustrated in Figure 5, the fusion is initiated by a low pH-induced
dissociation of the antiparallel E:M:M:E heterotetramers, followed by the exposure of the hydrophobic
fusion loop of each E protein, its insertion only partway into the outer bilayer leaflet of the host
cell membrane, and a large-scale structural rearrangement of the antiparallel E:E homodimer of the
E:M:M:E heterotetramers into a parallel E:E:E homotrimer [330,423,425,435]; however, the fate of the
antiparallel M:M homodimers is unknown. In the post-fusion E:E:E homotrimer, E-DIII folds back
against the central trimer, presumably with the helical stem extended from the C-terminus of E-DIII
along E-DII and toward the fusion loop (known as “zipping”) [264,265,436–441]. During this E-DIII
fold-back process, the overall structures of E-DI, E-DII, and E-DIII are maintained, but the relative
orientations of the three domains are rearranged. To date, the steps involved in the pH-induced
domain rearrangement and their underlying mechanisms are not completely understood.
It is conceivable that cellular proteins may assist in bringing to completion the low pH-initiated
membrane fusion and discharge of the viral nucleocapsid/genome into the cytoplasm, but they have
not yet been explored extensively. Earlier, a human genome-wide siRNA screen identified a collection
of host proteins involved in the early steps of WNV infection; one of these proteins, ubiquitin ligase
CBLL1 (Cbl-like protein 1, also known as Hakai), in conjunction with the ubiquitin-proteasome system
(UPS), has been suggested to play a critical role in a post-attachment step of WNV entry, such as
internalization [415]. The UPS has also been implicated in JEV entry, especially in a post-attachment step
prior to the initial translation of viral genomic RNA [443]. Interestingly, biochemical assays, combined
with live-cell imaging and single-particle tracking, have shown that in some flaviviruses (JEV and YFV),
the virus-host cell membrane fusion is a distinct event that precedes the microtubule-mediated release
of viral nucleocapsid/genome into the cytoplasm [444]. Even more intriguingly, a recent molecular
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biology-based study has demonstrated that during DENV entry, the release of viral genome or uncoating
of viral nucleocapsid is hampered by inhibiting ubiquitination [445]. In the same study, viral capsid
was shown to be degraded after internalization by the host UPS, although this event was not required
to release the viral genomic RNA into the cytoplasm for initial translation [445]. On the other hand,
another study has reported that the siRNA-based knockdown of CBLL1 expression has no significant
effect on the infection efficiency of several mosquito-borne flaviviruses (WNV, DENV, and YFV) in
human cells, and that treatment with proteasome inhibitors (MG132 and lactacystin) has no measurable
impact on the entry of WNV [446]. Thus, further investigation is needed to determine the precise role
of CBLL1 and UPS in the host-cell entry of JEV and other flaviviruses.
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Figure 5. Schematic presentation illustrating JEV E-mediated membrane fusion. The membrane fusion
event is initiated by the binding of a cellular receptor(s) to the viral pre-fusion E dimer of E:M:M:E
heterotetramers, followed by dissociation of the E dimers, insertion of the fusion loops into the host
cell membrane, trimerization of membrane-interacting E monomers, and changes in the E trimers
to the post-fusi n conf rmation. The diagram is modified from previously p blished work [442],
with minor odification. Shown below th diagram are the pre-fusion E dimer of JEV (PDB 3P54) and
the post-fusion E trimer of St. Louis encephalitis virus (SLEV, PDB 4FG0), a member of the JE serogroup.
5. Conclusions: JEV Entry Is an Area of High Interest for Future Research
Viral entry is the first step in an infection process that involves a cascade of multiple, highly
coordinated interactions between the virus and its target cells. This aspect of virus research is of
particular relevance because viral entry is a common feature essential to the initiation, dissemination,
and maintenance of productive infection by all human and animal viruses. Whereas the viral
factors involved in JEV entry are well defined (particularly viral glycoprotein E, which is involved
in attachment, endocytosis, and membrane fusion), the host factors that participate in this multistep
process remain poorly understood. To date, three types of multiple host factors (GAGs, C-type
lectins, and integrins), along with their interacting counterparts (basic residue-rich region, glycan,
and RGD motif, respectively) in the viral E glycoprotein, have been relatively well characterized as
attachment factors for a range of mammalian and/or mosquito cells for promoting the cell entry of
JEV and other flaviviruses, although they often act in a strain-specific and cell type-dependent manner.
However, the host entry factor(s) that can direct receptor-mediated endocytosis and low pH-dependent
membrane fusion once viral attachment has occurred remain elusive. In particular, identification of
the bona fide cell-surface receptor(s) responsible for JEV internalization has been a major challenge
in JEV biology, primarily because of a lack of availability of the nonsusceptible cell line that has a
block in JEV entry but can fully support the subsequent post-entry steps (translation, RNA replication,
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assembly, and release) and is therefore capable of serving as a platform cell line for receptor screening
and validation. Over the years, only a few cell lines have been described to be resistant to JEV infection
(e.g., human B lymphoblast Daudi [286] and mouse neuroblastoma N18TG2 [447]). With the use of
such a JEV-nonsusceptible cell line, two complementary genome-wide genetic screens for both the gain-
and loss-of-function of JEV entry can allow us to identify the host factors that are critical for JEV entry
and to dissect the discrete entry steps that are regulated by specific host factors. The outcomes of this
research will not only shed new light on the cell/tissue tropism and pathogenesis of JEV, and possibly
other closely related encephalitic flaviviruses, but also provide new targets for the development of
novel antiviral interventions capable of inhibiting the early steps of JEV infection.
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